Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Krystal Biotech, Inc. (KRYS) Balance Sheet

As of 2026-06-30 (10-Q), Krystal Biotech, Inc. (KRYS) reported total assets of $1.5B, total liabilities of $141.5M and shareholders' equity of $1.4B, according to EquiReason's reading of its SEC filings. Cash and equivalents: $427.7M.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

KRYSKrystal Biotech, Inc.Follow KRYS — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
9.2B
P/E TTM
39.0
Dividend yield
—
52-week
—
Next earnings
9 Nov, in 16 days
LineFY2017
Dec 17
FY2019
Dec 19
FY2020
Dec 20
FY2021
Dec 21
FY2022
Dec 22
FY2023
Dec 23
FY2024
Dec 24
FY2025
Dec 25
Latest
Jun 26
Trend
Cash and equivalents0.050.190.270.340.160.360.340.500.43
Short-term investments—0.010.000.100.220.170.250.330.42
Receivables————0.000.040.100.130.14
Inventory————0.000.010.030.040.05
Current assets0.050.200.280.440.380.590.741.021.06
Total assets0.050.210.310.630.560.821.061.331.50
Current liabilities0.000.000.020.030.030.030.100.100.13
Long-term debt0.00————————
Total liabilities0.000.010.020.030.040.040.110.110.14
Shareholders' equity0.050.200.290.590.520.780.951.221.36

USD billions · SEC XBRL

Krystal Biotech, Inc. — questions

How much cash does Krystal Biotech, Inc. have?
$427.7M in cash and cash equivalents as of 2026-06-30.
What are Krystal Biotech, Inc.'s total assets?
$1.5B as of 2026-06-30.
What is Krystal Biotech, Inc.'s shareholders' equity?
$1.4B as of 2026-06-30.

Every figure on this page comes from Krystal Biotech, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.